title: [ESBL and carbapenemases in Enterobacteriaceae].
abstract: Carbapenemase-producing enterobacteria (CPE) spread all over the world during the last years, causing serious infections with increasing frequency. Very few new drugs active against CPE are expected to be clinically available. Studies summarized in this review show that there is yet room to improve our therapeutic approaches, in the treatment of infections due to CPE.
authors.affiliation: Laboratoire de bactériologie, HUG, Genève. abdessalam.cherkaoui@hcuge.ch
authors.forename: A
authors.initials: A
authors.lastname: Cherkaoui
authors.forename: S
authors.initials: S
authors.lastname: Emonet
authors.forename: G
authors.initials: G
authors.lastname: Renzi
authors.forename: A
authors.initials: A
authors.lastname: Riat
authors.forename: G
authors.initials: G
authors.lastname: Greub
authors.forename: J
authors.initials: J
authors.lastname: Schrenzel
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000378:metabolism*; D015195:Drug Design; D004755:Enterobacteriaceae / Q000201:enzymology*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases / Q000378:metabolism*
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D001618:beta-Lactamases; C063912:carbapenemase